On January 6, 2022, Eli Lilly and Company and Entos Pharmaceuticals, Inc. announced that Lilly acquired exclusive rights to Entos’ Fusogenix nucleic acid delivery technology to research, develop and commercialize nucleic acid products targeting the central and peripheral nervous system.
As agreed, Entos will receive an initial payment of US$50 million, including an equity investment by Lilly, and will be eligible to receive up to US$400 million in potential developmental and commercial milestone payments, as well as royalties upon the successful development and commercialization of products, for each of the programs under the collaboration.
Lilly and Entos agreed to multiple programs focused on the development of proteo-lipid vehicles (PLV) for delivery of therapeutic cargo supplied by Lilly to targets in the central and peripheral nervous systems. Entos will be responsible for the generation, development and optimization of PLVs using its proprietary Fusogenix platform technology. Lilly will be responsible for selecting PLVs for clinical development and commercialization.